Mkt Cap $304M
52wk $0.75 - $5.54
3h ago
Insider buying: $25,876,165 bought by 6 insiders (30d)
Factor divergence:
DIVERGENCE: estimate_revisions, insider_activity, analyst_revisions bullish vs options_sentiment bea
Est. revisions:
+4.6%
(1 up, 0 down in 30d)
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net +2.0)
Factor Model
net +2.0 4.7 / 10
Est. Revisions
+0.3
Insider Activity
+0.5
Momentum
+0.0
Analyst Rev.
+1.0
Narrative Gap
+0.0
Goldman Sachs Starts PRLD Coverage Bullish
Watch: Upcoming clinical trial data for metastatic breast cancer will test growth projections and justify valuations.
Prelude Therapeutics saw $12.5M insider buys by Bonita David and OrbiMed Advisors at $4.44 per share. Goldman Sachs initiated coverage with an Early-Stage Biotech rating citing a $10B metastatic breast cancer opportunity. Q1 2026 EPS beat expectations at -$0.13 versus -$0.27 consensus and cash runway extends to Q2 2028.
The heavy insider buying and analyst initiation highlight confidence in Prelude's growth potential and financial stability in a challenging biotech sector.
Evidence
3h ago
Insider buy by VADDI KRISHNA (PRLD): $6,044
3h ago
Insider buy by VADDI KRISHNA (PRLD): $69,564
3h ago
Insider buy by VADDI KRISHNA (PRLD): $29,460
3h ago
Insider buy by VADDI KRISHNA (PRLD): $14,909
3h ago
Insider buy by COMBS ANDREW P (PRLD): $69,250
3h ago
Insider buy by VADDI KRISHNA (PRLD): $467,438
3h ago
Insider buy by ORBIMED ADVISORS, L.L.C. (PRLD): $12,499,999
3h ago
Insider buy by BONITA DAVID P. M.D. (PRLD): $12,499,999
5 older signals
3h ago
Insider buy by VADDI KRISHNA (PRLD): $99,326
3h ago
Insider buy by LIM BRYANT DAVID (PRLD): $22,638
3h ago
Insider buy by COMBS ANDREW P (PRLD): $85,538
3h ago
Insider buy by VADDI KRISHNA (PRLD): $12,000
Fundamentals & Data ▾
Prelude Therapeutics Incorporated
Healthcare · Biotechnology
Mkt Cap
$304M
Beta
1.10
52w Range
$0.75 - $5.54
Short Interest
1.9M 7.36%
Days to Cover
3.2 +2%
Insiders
buying
12B / 0S
EPS Estimate
$-0.24
+4.6% 30d
1up / 0dn
Est. Dispersion
41%
3 analysts
Analyst Target
$8
$6 - $10
Options P/C
1.61
Insider Cluster
strong buy
5B / 0S (officer)
Fund Convergence
moderate
Renaissance, Two Sigma
Financials
Revenue
$5M
FCF
$-22M
Op Margin
-310%
Momentum:
decelerating
Top Holders
Renaissance
Two Sigma
Recent Filings & Data
insider trade
14
net buying
· $25,876,165 bought
6 insiders · 14 transactions (30d)
Recent transactions
BONITA DAVID P. M.D. · buy · $12,499,999
ORBIMED ADVISORS, L.L.C. · buy · $12,499,999
HUANG JANE · other
VADDI KRISHNA · buy · $467,438
COMBS ANDREW P · buy · $69,250
VADDI KRISHNA · buy · $14,909
VADDI KRISHNA · buy · $29,460
VADDI KRISHNA · buy · $69,564
VADDI KRISHNA · buy · $6,044
VADDI KRISHNA · buy · $12,000
COMBS ANDREW P · buy · $85,538
LIM BRYANT DAVID · buy · $22,638
VADDI KRISHNA · buy · $99,326
HUANG JANE · other
13 signals · latest 3h ago
Keep reading the market
Direction shifts, insider clusters, filing red flags, and earnings call changes stay published on the site.